Comparison of electrophysiological effects of palonosetron and tolansetron on cardiac patients undergoing surgery

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044888

Enrollment

Unknown

Registered

2021-03-31

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Electrophysiology of heart

Interventions

H1 group:palonosetron 0.15mg

H2 group:tolansetron 5mg

control group:normal saline

Eligibility

Sex/Gender

All

Age

65 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Age >= 65; 2.Cardiopulmonary function and electrolyte were normal before surgery, ECG was normal, QT interval and heart rate corrected QT interval < 440 ms; 3.No antiarrhythmic drugs, ß-blockers, antidepressants and other drugs to prolong QT interval; 4.No endocrine diseases.

Exclusion criteria

Exclusion criteria: 1.Patients with allergy to palonosetron or tolansetron; 2.Severe preoperative organic lesions; 3.History of severe motion sickness.

Countries

China

Contacts

Public ContactLiu Yanqiu

Guiyang Fourth People's Hospital

1150725102@qq.com+86 18198618386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026